Berenberg Bank set a €28.00 ($32.56) price target on Evotec (ETR:EVT) in a report published on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Separately, Deutsche Bank set a €25.00 ($29.07) price target on Evotec and gave the company a buy rating in a research report on Thursday, September 5th.
EVT stock traded up €0.36 ($0.42) during trading on Thursday, hitting €20.89 ($24.29). 1,367,971 shares of the company traded hands, compared to its average volume of 1,360,000. The stock’s 50-day simple moving average is €22.66 and its 200 day simple moving average is €22.81. The company has a debt-to-equity ratio of 99.79, a current ratio of 3.24 and a quick ratio of 3.01. The company has a market cap of $3.12 billion and a PE ratio of 41.12. Evotec has a 1 year low of €15.00 ($17.44) and a 1 year high of €27.29 ($31.73).
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.